Synergistic Anti-Cancer Effects of Icariin and Temozolomide in Glioblastoma

Cell Biochemistry and Biophysics

Volumn 71, Issue 3, 2015, Pages 1379-1385

  Yang, Lijuan ^a   Wang, Yuexun ^b   Guo, Hua ^a   Guo, Meiling ^b  

^a SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

^b First People's Hospital of Jining   (China)

Author keywords

AMPK; GBM; Icariin; TMZ

Indexed keywords

ANTINEOPLASTIC AGENT; DACARBAZINE; FLAVONOID; ICARIIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; TEMOZOLOMIDE;

ANALOGS AND DERIVATIVES; APOPTOSIS; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; DRUG POTENTIATION; GLIOBLASTOMA; HUMAN; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE; TUMOR INVASION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DACARBAZINE; DRUG SYNERGISM; FLAVONOIDS; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 84930089299     PISSN: 10859195     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12013-014-0360-3     Document Type: Article

References (31)

1. Surawicz, T. S., Davis, F., Freels, S., Laws, E. R, Jr., & Menck, H. R. (1998). Brain tumor survival: Results from the National Cancer Data Base. Journal of Neuro-oncology,40, 151–160.
2. Furnari, F. B., Fenton, T., Bachoo, R. M., Mukasa, A., Stommel, J. M., Stegh, A., et al. (2007). Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes & Development,21, 2683–2710.
3. Grossman, S. A., & Batara, J. F. (2004). Current management of glioblastoma multiforme. Seminars in Oncology,31, 635–644.
4. Quick, A., Patel, D., Hadziahmetovic, M., Chakravarti, A., & Mehta, M. (2010). Current therapeutic paradigms in glioblastoma. Reviews on Recent Clinical Trials,5, 14–27.
5. Uzzaman, M., Keller, G., & Germano, I. M. (2007). Enhanced proapoptotic effects of tumor necrosis factor-related apoptosis-inducing ligand on temozolomide-resistant glioma cells. Journal of Neurosurgery,106, 646–651.
6. Aoki, T., Mizutani, T., Ishikawa, M., Sugiyama, K., & Hashimoto, N. (2003). A first feasibility study of temozolomide for Japanese patients with recurrent anaplastic astrocytoma and glioblastoma multiforme. International Journal of Clinical Oncology,8, 301–304.
7. Chen, Y., Huang, J. H., Ning, Y., & Shen, Z. Y. (2011). Icariin and its pharmaceutical efficacy: Research progress of molecular mechanism. Zhong Xi Yi Jie He Xue Bao,9, 1179–1184.
8. Zhang, D. C., Liu, J. L., Ding, Y. B., Xia, J. G., & Chen, G. Y. (2013). Icariin potentiates the antitumor activity of gemcitabine in gallbladder cancer by suppressing NF-kappaB. Acta Pharmacologica Sinica,34, 301–308.
9. Huang, X., Zhu, D., & Lou, Y. (2007). A novel anticancer agent, icaritin, induced cell growth inhibition, G1 arrest and mitochondrial transmembrane potential drop in human prostate carcinoma PC-3 cells. European Journal of Pharmacology,564, 26–36.
10. Li, S., Dong, P., Wang, J., Zhang, J., Gu, J., Wu, X., et al. (2010). Icariin, a natural flavonol glycoside, induces apoptosis in human hepatoma SMMC-7721 cells via a ROS/JNK-dependent mitochondrial pathway. Cancer Letters,298, 222–230.
11. Lin, C. C., Ng, L. T., Hsu, F. F., Shieh, D. E., & Chiang, L. C. (2004). Cytotoxic effects of Coptis chinensis and Epimedium sagittatum extracts and their major constituents (berberine, coptisine and icariin) on hepatoma and leukaemia cell growth. Clinical and Experimental Pharmacology and Physiology,31, 65–69.
12. Wang, Y., Dong, H., Zhu, M., Ou, Y., Zhang, J., Luo, H., et al. (2010). Icariin exterts negative effects on human gastric cancer cell invasion and migration by vasodilator-stimulated phosphoprotein via Rac1 pathway. European Journal of Pharmacology,635, 40–48.
13. Wang, Q., Hao, J., Pu, J., Zhao, L., Lu, Z., Hu, J., et al. (2011). Icariin induces apoptosis in mouse MLTC-10 Leydig tumor cells through activation of the mitochondrial pathway and down-regulation of the expression of piwil4. International Journal of Oncology,39, 973–980.
14. Li, L., & Wang, X. M. (2008). Progress of pharmacological research on icariin. Zhongguo Zhong yao za zhi,33, 2727–2732.
15. Chou, T. C., & Talalay, P. (1984). Quantitative analysis of dose–effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Advances in Enzyme Regulation,22, 27–55.
16. Wang, Y. W., Wang, S. J., Zhou, Y. N., Pan, S. H., & Sun, B. (2012). Escin augments the efficacy of gemcitabine through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in pancreatic cancer both in vitro and in vivo. Journal of Cancer Research and Clinical Oncology,138, 785–797.
17. Stupp, R., Mason, W. P., van den Bent, M. J., Weller, M., Fisher, B., Taphoorn, M. J., et al. (2005). Organisation for, T. Treatment of Cancer Brain, G. Radiotherapy, G. National Cancer Institute of Canada Clinical Trials, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. The New England journal of medicine,352, 987–996.
18. Ma, H. R., Wang, J., Chen, Y. F., Chen, H., Wang, W. S., & Aisa, H. A. (2014). Icariin and icaritin stimulate the proliferation of SKBr 3 cells through the GPER1-mediated modulation of the EGFR-MAPK signaling pathway. International Journal of Molecular Medicine,33, 1627–1634.
19. Li, F., Gong, Q. H., Wu, Q., Lu, Y. F., & Shi, J. S. (2010). Icariin isolated from Epimedium brevicornum Maxim attenuates learning and memory deficits induced by d-galactose in rats. Pharmacology, Biochemistry and Behavior,96, 301–305.
20. Yuan, Y., Xue, X., Guo, R. B., Sun, X. L., & Hu, G. (2012). Resveratrol enhances the antitumor effects of temozolomide in glioblastoma via ROS-dependent AMPK-TSC-mTOR signaling pathway. CNS Neuroscience & Therapeutics,18, 536–546.
21. Filippi-Chiela, E. C., Thome, M. P., Bueno e Silva, M. M., Pelegrini, A. L., Ledur, P. F., Garicochea, B., et al. (2013). Resveratrol abrogates the temozolomide-induced G2 arrest leading to mitotic catastrophe and reinforces the temozolomide-induced senescence in glioma cells. BMC cancer,13, 147.
22. Huang, H., Lin, H., Zhang, X., & Li, J. (2012). Resveratrol reverses temozolomide resistance by downregulation of MGMT in T98G glioblastoma cells by the NF-kappaB-dependent pathway. Oncology Reports,27, 2050–2056.
23. Kunnumakkara, A. B., Diagaradjane, P., Guha, S., Deorukhkar, A., Shentu, S., Aggarwal, B. B., et al. (2008). Curcumin sensitizes human colorectal cancer xenografts in nude mice to gamma-radiation by targeting nuclear factor-kappaB-regulated gene products. Clinical Cancer Research,14, 2128–2136.
24. Naugler, W. E., & Karin, M. (2008). NF-kappaB and cancer-identifying targets and mechanisms. Current Opinion in Genetics & Development,18, 19–26.
25. Nogueira, L., Ruiz-Ontanon, P., Vazquez-Barquero, A., Moris, F., & Fernandez-Luna, J. L. (2011). The NFkappaB pathway: A therapeutic target in glioblastoma. Oncotarget,2, 646–653.
26. Atkinson, G. P., Nozell, S. E., & Benveniste, E. T. (2010). NF-kappaB and STAT3 signaling in glioma: targets for future therapies. Expert Review of Neurotherapeutics,10, 575–586.
27. Caporali, S., Levati, L., Graziani, G., Muzi, A., Atzori, M. G., Bonmassar, E., et al. (2012). NF-kappaB is activated in response to temozolomide in an AKT-dependent manner and confers protection against the growth suppressive effect of the drug. Journal of Translational Medicine,10, 252.
28. Markiewicz-Zukowska, R., Borawska, M. H., Fiedorowicz, A., Naliwajko, S. K., Sawicka, D., & Car, H. (2013). Propolis changes the anticancer activity of temozolomide in U87MG human glioblastoma cell line. BMC Complementary and Alternative Medicine,13, 50.
29. Sai, K., Li, W. Y., Chen, Y. S., Wang, J., Guan, S., Yang, Q. Y., et al. (2014). Triptolide synergistically enhances temozolomide-induced apoptosis and potentiates inhibition of NF-kappaB signaling in glioma initiating cells. The American Journal of Chinese Medicine,42, 485–503.
30. Brassesco, M. S., Roberto, G. M., Morales, A. G., Oliveira, J. C., Delsin, L. E., Pezuk, J. A., et al. (2013). Inhibition of NF-kappa B by Dehydroxymethylepoxyquinomicin Suppresses Invasion and Synergistically Potentiates Temozolomide and gamma-radiation cytotoxicity in glioblastoma Cells. Chemotherapy Research and Practice,2013, 593020.
31. Chen, M., Rose, A. E., Doudican, N., Osman, I., & Orlow, S. J. (2009). Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Molecular Cancer Research,7, 1946–1953.